临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 1346528-50-4

JNJ-42165279

中文名称:N-(4-氯-3-吡啶基)-4-[(2,2-二氟-1,3-苯并二恶茂-5-基)甲基]-1-哌嗪甲酰胺
CAS号:1346528-50-4
分子式: C18H17ClF2N4O3 分子量: 410.80
产品形式: Free Base
研发状态: Completed
研发用途: Healthy
研究机构: Janssen Research & Development LLC
研发日期: June 12 2018
研发阶段: Phase 1
JNJ-42165279 (JNJ-5279) is an inhibitor of fatty acid amide hydrolase (FAAH) that inhibits recombinant human and rat FAAH with IC50 of 70 nM and 313 nM, respectively.

CAS: 1346242-81-6

Erdafitinib (JNJ-42756493)

中文名称:厄达替尼
CAS号:1346242-81-6
分子式: C25H30N6O2 分子量: 446.54
产品形式: free base
研发状态: Recruiting
研发用途: Urinary Bladder Neoplasms; Receptors Fibroblast Growth Factor
研究机构: Janssen Pharmaceutical K.K.
研发日期: March 3 2023
研发阶段: Phase 1
Erdafitinib (JNJ-42756493) is a potent and selective orally bioavailable, pan fibroblast growth factor receptor (FGFR) inhibitor with potential antineoplastic activity. Erdafitinib also binds to RET (c-RET), CSF-1R, PDGFR-α/PDGFR-β, FLT4, Kit (c-Kit) and VEGFR-2 and induces cellular apoptosis.

CAS: 1345407-05-7

Ruxotemitide (LTX 315)

CAS号:1345407-05-7
分子式: C78H106N18O9 分子量: 1439.79
产品形式: free base
研发状态: Completed
研发用途: Soft Tissue Sarcoma
研究机构: Lytix Biopharma AS; Herlev Hospital
研发日期: December 28 2018
研发阶段: Phase 2
Ruxotemitide (LTX 315, Oncopore) is the oncolytic peptide that kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization.

CAS: 134523-03-8

Atorvastatin Calcium

中文名称:阿托伐他汀钙
CAS号:134523-03-8
分子式: 2(C33H34FN2O5).Ca 分子量: 1155.34
产品形式: Calcium
研发状态: Withdrawn
研发用途: Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer; Stage IV Prostate Cancer
研究机构: University of Nebraska; National Cancer Institute (NCI)
研发日期: Mar-12
研发阶段: Not Applicable
Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of cholesterol. Atorvastatin Calcium induces apoptosis and autophagy.

CAS: 134308-13-7

Tolcapone

中文名称:托卡朋
CAS号:134308-13-7
分子式: C14H11NO5 分子量: 273.24
产品形式: free base
研发状态: Completed
研发用途: Transthyretin Amyloidosis; Amyloidosis Leptomeningeal Transthyretin-Related
研究机构: Boston University; Corino Therapeutics Inc.
研发日期: October 30 2018
研发阶段: Early Phase 1
Tolcapone (Ro 40-7592) is a selective, potent and reversible of catechol-O-methyl transferase (COMT) inhibitor with Ki of 30 nM.

CAS: 13422-55-4

Methylcobalamin

中文名称:甲钴胺
CAS号:13422-55-4
分子式: C63H91CoN13O14P 分子量: 1344.38
产品形式: inner salt
研发状态: Completed
研发用途: Bariatric Surgery Candidate; Vitamin Deficiency; Mineral Deficiency
研究机构: University of Florida
研发日期: December 15 2017
研发阶段: --
Methylcobalamin (Mecobalamin, Vancomin, Methycobal, Cobametin) is one active form of vitamin B12 which can directly participate in homocysteine metabolism. It is used to treat some nutritional diseases and other diseases in clinic, such as Alzheimer's disease and rheumatoid arthritis.